Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;38(6):393-401.
doi: 10.1016/j.revmed.2016.10.392. Epub 2016 Nov 21.

[Neurosarcoidosis: Diagnosis and therapeutic issues]

[Article in French]
Affiliations
Review

[Neurosarcoidosis: Diagnosis and therapeutic issues]

[Article in French]
F Cohen Aubart et al. Rev Med Interne. 2017 Jun.

Abstract

Neurological localizations of sarcoidosis are heterogeneous and may affect virtually every part of the central or peripheral nervous system. They are often the inaugural manifestation of sarcoidosis. The diagnosis may be difficult due to the lack of extra-neurological localization. Diagnosis may be discussed in the presence of an inflammatory neurological disease, in particular in case of suggestive radiological or biological pattern. Cerebrospinal fluid analysis shows lymphocytic pleiocytosis, often with low glucose level. The diagnosis relies on a clinical, biological and radiological presentation consistent with neurosarcoidosis, the presence of non-caseating granuloma and exclusion of differential diagnoses. Screening for other localizations of sarcoidosis, in particular cardiac disease may be obtained during neurosarcoidosis. The treatment of neurosarcoidosis relies on corticosteroids although immunosuppressive drugs are usually added because of the chronic course of this condition and to limit the side effects of steroids. Treatments and follow-up may be prolonged because of the high rate of relapses.

Keywords: Antagonistes du TNFα; Corticosteroids; Corticostéroïdes; Granulomas; Granulome; Immunosuppresseurs; Immunosuppressive drugs; Neurosarcoidosis; Neurosarcoïdose; Sarcoidosis; Sarcoïdose; TNFα antagonists.

PubMed Disclaimer

MeSH terms

Substances

Supplementary concepts